Article
A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.
Cancer research - 15 Jun 2026
Wang Chen, Sun Ting, He Yufei, Yu Mingchen, Pan Chang-Qing, Hu Huimin, Sun Yishuo, Wang Di, Cui Zhongliang, Zhang Jiazheng, Zhai You, Shi Zhongfang, Li Ziwei, Xu Menghui, Oh Young Taek, Jiang Tao, Xu Zhiyuan, Li Guanzhang, Zhang Jing, Zhang Wei
Abstract excerpt
Glioblastoma (GBM) is the most common malignant intracranial tumor in adults, with a median survival of only 16 to 20 months. Neoantigen therapy has shown advantages in the treatment of GBM, as it improves the immunosuppressive microenvironment within the tumor. However, the identification of truly immunogenic neoantigens remains a major challenge. Current computational prediction tools primarily focus on antigen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.